-
CymaBay Therapeutics to Present at Upcoming Investor Conferences in September
-
CymaBay Therapeutic (CBAY) PT Lowered to $12 at Citi
-
Citi Starts CymaBay Therapeutic (CBAY) at Buy
-
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
CymaBay Therapeutics (CBAY) Prices 8M Common Stock Offering at $12.50/Share
-
CymaBay Announces Pricing of Public Offering of Common Stock
-
CymaBay Therapeutics (CBAY) to Offer Common Stock
-
CymaBay Announces Proposed Public Offering of Common Stock
-
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September
-
Omega's 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More...)
-
CymaBay Therapeutics (CBAY) Names Sujal Shah as President and CEO
-
CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer
-
CymaBay Therapeutics (CBAY) CEO Harold Van Wart to Retire
-
CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.

